A bipartisan group of 175 members of Congress has called on the Trump administration to investigate safety concerns surrounding mifepristone, the first drug in the two-pill abortion regimen.
The lawmakers highlighted a recent study showing that serious complications occur 22 times more often than FDA reports indicate, including infection, hemorrhaging, sepsis, and other adverse effects.
The letter to HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Martin Makary requests an immediate reinstatement of the in-person dispensing requirement, which ensures women receive proper medical oversight. Lawmakers, including pro-life leaders Rep. Chris Smith and Rep. Diana Harshbarger, emphasized that the current mail-order system under the Biden administration endangers women’s health by allowing unsupervised access to abortion drugs.
Read the letter here.